Prolonged time to treatment of biologics in inflammatory bowel disease: disparities from a retrospective study in a tertiary referral centre in the UK
Delays in initiating biologic therapy are significantly associated with IBD type, ethnicity and therapy type. Unwarranted variation in IBD care can be mitigated by concerted initiatives to address modifiable factors for timely access to effective therapies.
Authors
- Nikolaos Kamperidis (ORCID: https://orcid.org/0000-0003-2543-1723)
- Charlotte Wong (ORCID: https://orcid.org/0000-0002-3783-3810)
- Naila Arebi (ORCID: https://orcid.org/0000-0001-6976-1690)
- Paul Bassett (ORCID: https://orcid.org/0000-0001-7830-4563)
- Lovesh Dyall
- Ravi Misra (ORCID: https://orcid.org/0000-0003-0113-9971)
- Katie Yeung (ORCID: https://orcid.org/0000-0003-3629-9131)
- Lisa Younge (ORCID: https://orcid.org/0000-0002-3436-9696)
- Christy Rejee
Institutions
- St Mark's Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1186/s12876-025-03909-9
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer